Logo
x

Search category

Subscribe Now

Vertex

Vertex Receives EC’s Approval for the Label Extension of Orkambi to Treat Children with Cystic Fibrosis Aged 1 to <2 Years

Vertex Receives EC’s Approval for the Label Extension of Orkambi to Treat Children with Cystic Fibrosis Aged 1 to <2 Years

  • July 5, 2023
Vertex’s Orkambi (lumacaftor/ivacaftor) Receives EMA’s CHMP Positive Opinion for Children With Cystic Fibrosis Ages 1 to <2 Years

Vertex’s Orkambi (lumacaftor/ivacaftor) Receives EMA’s CHMP Positive Opinion for Children With Cystic Fibrosis Ages 1 to <2 Years

  • April 27, 2023
Vertex’s Trikafta Receives the US FDA’s Approval for the Treatment of Children with Cystic Fibrosis Aged 2 Through 5 Years

Vertex’s Trikafta Receives the US FDA’s Approval for the Treatment of Children with Cystic Fibrosis Aged 2 Through 5 Years

  • April 26, 2023
Vertex’s Orkambi (lumacaftor/ivacaftor) Receives Health Canada’s Market Authorization for Children with Cystic Fibrosis Aged 1 to <2 Years

Vertex’s Orkambi (lumacaftor/ivacaftor) Receives Health Canada’s Market Authorization for Children with Cystic Fibrosis Aged 1 to...

  • April 11, 2023
Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Diabetes

Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Dia...

  • March 28, 2023
Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes

Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes

  • March 10, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.